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Bipolar disorder (BD) is a significant neuropsychiatric disorder with a lifetime prevalence
of ∼1%. To identify genetic variants underlying BD genome-wide association studies
(GWAS) have been carried out. While many variants of small effect associated with BD
have been identified few have yet been confirmed, partly because of the low power of
GWAS due to multiple comparisons being made. Complementary mapping studies using
murine models have identified genetic variants for behavioral traits linked to BD, often
with high power, but these identified regions often contain too many genes for clear
identification of candidate genes. In the current study we have aligned human BD GWAS
results and mouse linkage studies to help define and evaluate candidate genes linked
to BD, seeking to use the power of the mouse mapping with the precision of GWAS.
We use quantitative trait mapping for open field test and elevated zero maze data in the
largest mammalian model system, the BXD recombinant inbred mouse population, to
identify genomic regions associated with these BD-like phenotypes. We then investigate
these regions in whole genome data from the Psychiatric Genomics Consortium’s bipolar
disorder GWAS to identify candidate genes associated with BD. Finally we establish the
biological relevance and pathways of these genes in a comprehensive systems genetics
analysis. We identify four genes associated with both mouse anxiety and human BD.
While TNR is a novel candidate for BD, we can confirm previously suggested associations
with CMYA5, MCTP1, and RXRG. A cross-species, systems genetics analysis shows
that MCTP1, RXRG, and TNR coexpress with genes linked to psychiatric disorders and
identify the striatum as a potential site of action. CMYA5, MCTP1, RXRG, and TNR are
associated with mouse anxiety and human BD. We hypothesize thatMCTP1, RXRG, and
TNR influence intercellular signaling in the striatum.
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Introduction
Bipolar disorder (BD) is a neuropsychiatric disorder characterized by recurrent periods of mania
and depression. Bipolar I disorder has a lifetime prevalence (i.e., at least one case of both depression
and mania) of∼1%, although the bipolar spectrum (at least one episode of sub-threshold mania or
hypomania) has a lifetime prevalence of up to 6.4% (Judd and Akiskal, 2003; Merikangas et al.,
2007). Twin studies estimate heritability of ∼60–80%, indicating a substantial genetic component
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(McGuffin et al., 2003; Edvardsen et al., 2008; Lichtenstein et al.,
2009; Wray and Gottesman, 2012).
To identify genetic variants underlying the disorder many
genome-wide association studies (GWAS) have been conducted
showing that BD is highly polygenic, with many single nucleotide
polymorphisms (SNPs) each of small effect (Ferreira et al.,
2008; Purcell et al., 2009; Scott et al., 2009; Psychiatric GWAS
Consortium Bipolar DisorderWorking Group, 2011). Due to this
polygenic nature large sample sizes are required to detect SNPs
with genome-wide significance. Indeed, despite large cohorts of
patients used, GWAS have found only 10 SNPs which are strongly
and consistently associated with the disorder (Szczepankiewicz,
2013; Mühleisen et al., 2014), although many genes have been
identified with lower confidence or using additional analyses. For
example, a recent pathway analysis study has linked 226 genes
to BD (Nurnberger et al., 2014), however, approximately 5% of
these would be expected to be false positives and the method is
biased against genes of small size (Nurnberger et al., 2014). In
order to understand the etiology and biology of bipolar disorder
it is critical to know the underlying causal variants. This allows us
to link the disorder to specific proteins and pathways, potentially
leading to novel treatments and a better ability to predict genetic
predisposition.
GWAS in humans typically have modest statistical power due
to high multiple testing corrections. However, loci are defined
with high precision, often to the individual SNP level. By contrast,
mouse linkage studies often have high statistical power to detect
genetic effects but lower resolution, producing loci that include
tens or hundreds of genes (Mackay et al., 2009; Ackert-Bicknell
et al., 2010; Hager et al., 2012; Wu et al., 2014). Combining
data from mice and humans overcomes some of these problems,
gaining power from mouse crosses and precision from human
GWAS. This method also ensures translational relevance, as the
same gene controlling similar phenotypes is found in a related
species (Ashbrook et al., 2014).Moreover, the approach illustrates
that the mouse homolog is relevant to the human phenotype,
allowing research to be carried out on the gene to phenotype
pathway which would not be possible in humans (Kas et al.,
2007).
Mammalian model systems have been extensively used to
investigate the genetic basis of disease traits through the
experimental study of analogous behavioral or developmental
traits (e.g., Hayes et al., 2014). We chose to investigate BD,
as several of the symptoms are related to behaviors which can
be measured in mice. For example, in manic patients typical
behaviors include motor hyperactivity, increased risk taking
and impulsive behavior (Goodwin and Jamison, 1990). Indeed,
anxiety and activity measures in mice have previously been
used to evaluate animal models of BD (Gould et al., 2001;
Kirshenbaum et al., 2011). Furthermore, up to 93% of bipolar
I disorder patients have a comorbid anxiety disorder at some
stage of their life, and comorbidity between BD and anxiety
results in significantly worse patient outcomes (Freeman et al.,
2002; MacKinnon, 2002; Boylan et al., 2004; Simon et al., 2004;
Merikangas et al., 2007; Goldstein and Levitt, 2008; Goodwin and
Sachs, 2010; Vázquez et al., 2014). Further, measures of global
anxiety correlate well with time spent in depressive episodes
in bipolar patients (Coryell et al., 2009).This suggests a shared
underlying etiology of anxiety and BD. Therefore, there is a clear
relationship between symptoms of bipolar disorder (Goodwin
and Sachs, 2010), behaviors disrupted in bipolar patients (Young
et al., 2007; Perry et al., 2009; Minassian et al., 2011) and
measureable behaviors in mice (Figure 1).
Most organisms will balance risk against potential reward;
whether to put greater emphasis on minimizing exposure to
danger (being more anxious), or greater emphasis on reward
(being more risk taking) (Marks and Nesse, 1994; Bateson
et al., 2011). This trade-off is reflected in a number of
behavioral patterns, and individuals in a population differ in the
degree to which anxiety-like behavior is displayed (Erhardt and
Spoormaker, 2013). Since normal and clinical anxiety exist upon
a continuum (Bateson et al., 2011) and aspects of pathological
anxiety and BD overlap in terms of etiology and phenotype, it is
reasonable to assume that some aspects of the underlying anxiety
system should also overlap with BD, although true anxiety is
more easily segregated from bipolar disorder in humans.
Previous studies demonstrated the utility of using a cross-
species approach to identify genes underlying specific traits (De
Mooij-van Malsen et al., 2009; Koutnikova et al., 2009; Leduc
et al., 2011; Poot et al., 2011; Schofield et al., 2012; Ashbrook
et al., 2014). This approach has the advantage that it allows
the investigation of phenotypes without requiring experimental
perturbations. We utilize data obtained from populations that
segregated for large numbers of common sequence variants and
associated differences in phenotype (Ashbrook et al., 2014). Here,
we use data for two common measures of anxiety and activity in
mouse, the elevated zero maze and the open field test, to identify
QTL in the largest mammalian model system, the recombinant
inbredmouse panel BXD (Wu et al., 2014). This identifies areas of
the genome containing genetic variants which influence BD-like
phenotypes in mice, and therefore may be influencing aspects of
BD in humans. These genomic regions were then investigated in
a large humanGWAS of BD, the SNP summary of which has been
made available online (Psychiatric GWAS Consortium Bipolar
Disorder Working Group, 2011). We identify four genes (TNR,
RXRG, MCTP1, and CMYA5) associated with anxiety in mice
and risk of BD in humans. A systems genetics approach suggests
that TNR, RXRG, andMCTP1 coexpress with several other genes
related to mental disorders in the striatum, providing a potential
mechanism of action.
Methods and Materials
Mouse and Human Data
The BXD recombinant inbred population consists of
experimentally tractable and genetically defined mouse lines
capturing a large amount of naturally occurring genetic variation,
which underlies variation at the phenotypic level (e.g., Chesler
et al., 2005; Mozhui et al., 2011; Hager et al., 2012). Over 140
BXD lines incorporate ∼5 million segregating SNPs, 500,000
insertions and deletions, and 55,000 copy-number variants
(Mozhui et al., 2011). These lines are used for complex systems
genetics analyses integrating massive phenotype and gene
expression data sets obtained in different studies (Andreux
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FIGURE 1 | Bipolar disorder traits and analogous mouse phenotypes.
On the left, symptoms of the manic and depressive phases of bipolar
disorder are shown, as well as behaviors which have been demonstrated to
be disrupted in bipolar disorder patients. On the right are mouse phenotypes
which are measured by the zero maze and open field test, showing how the
human traits link to the mouse traits.
et al., 2012; Hayes et al., 2014). For our analysis we used
data for two murine phenotypes, the elevated zero maze and
open field test (Philip et al., 2010) available in GeneNetwork
(genenetwork.org; February 2015) that measure a combination
of anxiety, exploration and activity (Henry et al., 2010), all of
which are altered in BD (Goodwin and Jamison, 1990; Young
et al., 2007). We selected traits with at least one significant QTL
(p ≤ 0.05) at the genome-wide level. Significance was calculated
within GeneNetwork, using 5000 permutations of trait values
and genotypes. A p-value of 0.05 is defined as an LRS score
greater than 95% of the permuted datasets (Wang et al., 2003).
Human GWAS data for BD were obtained from the
Psychiatric Genomics Consortium (PGC; https://pgc.unc.edu),
containing 11,974 BD cases and 51,792 controls (Psychiatric
GWAS Consortium Bipolar Disorder Working Group, 2011).
The majority of cases were of BD type 1 although also included
BD type 2, schizoaffective disorder bipolar type and individuals
with other bipolar diagnoses (Psychiatric GWAS Consortium
Bipolar Disorder Working Group, 2011). Knowledge-Based
Mining System for Genome-wide Genetic Studies (KGG; http://
statgenpro.psychiatry.hku.hk/limx/kgg; version 3.5) was used
to convert these SNP p-values to gene p-values, using both the
GATES and the hybrid set-based test (HYST) methods (Li et al.,
2010, 2011, 2012). The GATES test is a Simes test extension
that is valid for correlated SNPs, and, of the two methods, is
more powerful for genes with one or few independent causal
variants (Li et al., 2011). HYST combines the GATES test and
the scaled chi-square test (Moskvina et al., 2011) to examine the
overall association significance in a set of SNPs. This test is more
powerful for genes with a number of independent causal variants.
Both tests are advantageous as they require only summary GWAS
and ancestral population linkage disequilibrium data, rather
than raw data. Gene locations were from the Hg18 genome build.
We used the complete set of data from the Psychiatric Genomics
Consortium GWAS for BD (http://www.med.unc.edu/pgc/
downloads; pgc.bip.full.2012-04.txt), and linkage disequilibrium
data from the CEPH (Utah residents with ancestry from
northern and western Europe; CEU) Hapmap population dataset
(http://hapmap.ncbi.nlm.nih.gov/downloads/ld_data/?N=D).
For each gene in the Hg18 genome build a GATES and HYST
p-value was calculated for associated with bipolar disorder.
For the jointmouse—human analysis, the human homologs of
genes within the mouse QTL were identified using Homologene
(http://www.ncbi.nlm.nih.gov/homologene). To assess if any
particular gene is associated with both anxiety in mouse and
BD, we examined both the GATES derived and HYST derived p-
values of human homologs of genes within the significant BXD
QTL. The human GWAS significance values were Bonferroni
corrected for multiple comparisons using the total number of
homologous genes compared and the number of tests used (two:
HYST and GATES) (De Mooij-van Malsen et al., 2009; Ashbrook
et al., 2014).
Evolutionary Conservation
A highly conserved nucleotide sequence between mouse
and human would support that the protein plays the same
role in both species. For each gene the protein it codes for
was identified using the Entrez gene database (http://www.
ncbi.nlm.nih.gov/gene) and the NCBI reference sequence
for the protein identified. For each pair of homologous
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proteins a Protein BLAST was carried out with default settings
(http://blast.ncbi.nlm.nih.gov/Blast.cgi?PROGRAM=blastp&PA
GE_TYPE=BlastSearch&LINK_LOC=blasthome). The reference
sequences used were: RXRG human NP_001243499.1,
mouse NP_001153203.1; TNR human NP_003276.3,
mouse NP_071707.2; MCTP1 human NP_001002796.1,
mouse NP_084450.2; CMYA5 human NP_705838.3, mouse
NP_076310.2.
Identification of Areas of Expression
To identify the regions in themouse brain in which our candidate
genes are expressed we used images provided by the Allen
Brain Atlas showing patterns of gene expression (http://mouse.
brain-map.org; June 2015) throughout the adult mouse brain for
>20,000 genes, using in situ hybridization (Lein et al., 2007). For
the human data, the BrainSpan Atlas of the Developing Human
Brain (Miller et al., 2014) contains RNA-seq gene expression data
at different life stages. There are a total of 578 samples, covering
an age range from prenatal to 40 years and taken from 26 different
brain regions. To identify locations in the human brain where our
candidate genes are expressed we used gene expression heatmaps
that show levels of gene expression in different brain regions
(http://www.brainspan.org; June 2015).
“Guilt-by-Association”
To establish if specific genes are coexpressed in humans we
used GeneFriends (Van Dam et al., 2012; http://genefriends.
org/microArray/; January 2014) which contains microarray
data (4164 microarray datasets containing 26,113 experimental
conditions and 19,080 genes) from the Gene Expression
Omnibus (Van Dam et al., 2012; Barrett et al., 2013). This enabled
us to find genes that are commonly coexpressed (i.e., genes with a
coexpression value≥ 0.50 and a p ≤ 0.05) with a submitted gene
list. A coexpression value of 0.50 indicates that a particular gene
is increased in expression at least two-fold in 50% of the cases that
a target gene is increased in expression at least two-fold.
However, GeneFriends is not tissue or treatment specific, and
therefore can only show the genes that are coexpressed together,
not when or where. This common coexpression suggests that
the genes are under the same regulation. The list of commonly
coexpressed genes was analyzed using WebGestalt, producing
annotations for these genes. This “guilt-by-association” approach
enables us to identify the biological networks of our candidates
(Van Dam et al., 2012). WebGestalt (http://bioinfo.vanderbilt.
edu/webgestalt/; May 2014) is a web-based enrichment analysis
tool that incorporates information from online sources including
Gene Ontology (GO), KEGG pathways, Wikipathways, Pathways
Commons, and disease association analysis (Zhang et al., 2005;
Wang et al., 2013). The lists of genes generated by our “guilt-by-
association” analysis were submitted to WebGestalt to identify
pathways or diseases that our candidate genesmay be involved in.
Significance of enrichment was determined by the Benjamini and
Hochberg method of multiple test adjustment (Benjamini and
Hochberg, 1995) as implemented in WebGestalt, and the whole
human genome was used as the background set of genes.
Shared function of genes can be established using
coexpression analysis (Allocco et al., 2004). We analyzed
coexpression in adult mouse brain by producing Pearson
product-moment correlation matrices of striatal and
hippocampal gene expression (Chesler et al., 2003) as
implemented in GeneNetwork. The striatum was chosen as
it is an area where several of our genes are expressed, whereas
the hippocampus was chosen to identify if any coexpression seen
in the striatum was seen in other brain regions. Expression data
was obtained from GeneNetwork HQF Striatum Exon (Feb09)
RMA data (GN163) and UMUTAffy Hippocampus Exon
(Feb09) RMA (GN206). Since both used the same microarray
we could directly compare the data. Probes for exons were used
unless no exon probes were available, in which case introns
were investigated for consistent coexpression within a given
gene. Coexpression between our candidate genes and genes
previously associated with BD (as identified in Szczepankiewicz,
2013; Mühleisen et al., 2014), and other mental disorders
was calculated in GeneNetwork using Pearson correlations.
Multiple comparisons were corrected for by dividing the p-value
obtained in the correlation analysis by the number of probes
for our genes of interest (Cmya5, Mctp1, Rxrg, Tnr). Probes
were said to coexpress if they have an r ≥ 0.5 or ≤ −0.5
and an adjusted p ≤ 0.05. This allowed us to establish if our
candidate genes coexpress with genes known to be associated
with neuropsychiatric disorders, and whether this is specific to
the striatum.
Principal Component Analysis
Principal component analysis (PCA) was used to jointly analyze
multiple phenotypes including gene expression. PCA reduces
the dimensionality of data and captures the shared variability
between traits. If the first principal component (PC1) explains a
high proportion of the variability it can be used as a synthetic
trait, capturing the main common source of variation within the
traits (Mozhui et al., 2011). PCAwas carried out in GeneNetwork
to find the PC1 of striatal expression of our candidate gene
MCTP1 and the PC1 of the open field test phenotypes.
Biological Networks
In order to establish the biological networks of our candidate
genes we utilized the massive phenotype and expression data sets
available for the BXD panel (Gini and Hager, 2012; Ashbrook
and Hager, 2013). Generally, microarray analysis uses a number
of probes, targeted at different parts of a gene. Exon level
microarrays, such as those used above in the coexpression
analysis, can be used to calculate expression of exons, introns
or untranscribed regions (UTRs). Consistent correlation between
different probes for a gene and a phenotype would suggest that
the gene is associated with the phenotype.
First, using the same exon level data as used for the
coexpression analysis, probes for each of our four candidate gene
were examined for high Pearson correlation (r ≥ 0.5, p ≤ 0.05).
For each gene, this produced a group of highly correlated probes.
Each of these highly correlated probes was individually correlated
against BXD phenotypes, which yielded a list of phenotypes that
correlated with that probe (r ≥ 0.5 or ≤ −0.5 and p ≤ 0.05).
Next, the phenotypes which correlated with all the probes for a
particular candidate gene were identified, to produce a smaller list
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of phenotypes which consistently correlated with all the probes
for that gene.
Results
In Figure 2 we give a graphical summary of our results. We
begin by identifying QTL for the open field test and elevated
zero maze in the BXD recombinant inbred lines. We then
investigate the homologous genomic regions in human bipolar
disorder GWAS data and thus identify four candidate genes
(TNR, RXRG, MCTP1, and CMYA5). The protein products of
three of these genes (TNR, RXRG, and MCTP1) are highly
conserved (≥90% identical), and are expressed in the adult
striatum of both mouse and human. In non-tissue specific
human gene expression data these three genes coexpress with
genes that are associated with mental disorders. In the BXD
mouse striatum the three genes coexpress together, as well as
with known mental disorder related genes. Finally, when we
correlate striatal expression of all four of our candidate genes
against the large BXD phenotype dataset, we find that Tnr,
Rxrg, and Mctp1 expression correlates with dopamine related
traits, whereas Cmya5 expression correlates with anxiety- and
depression-like traits.
QTL for Bipolar Related Phenotypes in Mice
Bipolar disorder is characterized by disrupted anxiety, activity
and exploration (Goodwin and Jamison, 1990; Goodwin and
Sachs, 2010; Figure 1) and we thus investigated genetic variation
in those traits, focusing on the elevated zero maze and the
open field test. Both of these are used to measure anxiety,
activity and exploration in mice (Shepherd et al., 1994; Chauhan
et al., 2005; Kalueff et al., 2006; Ariyannur et al., 2013). We
FIGURE 2 | Graphical representation of the research method used, providing a summary of the main findings.
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limited the datasets to only those with no or saline only
treatment, and with at least one genome-wide significant QTL
(p ≤ 0.05).
For the seven available elevated zero maze traits, QTL
were consistently found on distal chromosome 1 (156.2–
175.3 Mbp), containing 185 genes with human homologs
(Table 1, Supplementary Figure 1). Therefore, the significance
threshold for human genes is p = 1.4e-4 (185 genes, each
compared against both the GATES andHYST significance values;
0.05/185∗2). However, the size of the above region differed
between the datasets, and appears to separate into two smaller
QTL, based on phenotypes showing either two peaks, with a
non-significant region between them, or a significant peak at
only one of the two QTL (Figure 3A; Supplementary Table 1;
Supplementary Figure 1).
The first QTL is located between 156.2 and 161.5Mbp
containing 30 homologous genes (significance threshold for
human genes p = 8.3e-4). Only one gene, TNR, has a p-value
lower than this threshold (GATES p = 7.48e-4; 161.4Mbp).
The second QTL is between 169.1 and 171.5Mbp, containing 9
homologous genes, with a p-value threshold of ≤ 2.7e-3. Only
one gene has a lower p-value, RXRG (GATES p = 9.63e-
4; 169.5Mbp). These two genes are the most significant genes
within this chromosome 1 region, and their positions line up well
with the LRS peaks in the QTL map (Figure 3A).
Consistent QTL for the 34 open field test phenotypes
are found on chromosome 13 (73–97Mbp), containing 63
homologous genes. The threshold for human genes is thus p ≤
3.96e-4. One gene has a p-values lower than this threshold:
CMYA5 (HYST p = 1.57e-4; 94.2Mbp). Interestingly, this
larger region again appears to segregate into two smaller QTL
(Table 2; Figure 3B; Supplementary Figure 2), the first from
73.3 to 84Mbp (41 homologous genes, p-value threshold= 6.1e-
4) and the second from 93.9 to 95.2Mbp (12 homologous genes,
p-value threshold= 2.1e-3). This reveals another significant gene,
MCTP1 (HYST p = 4.59e-4; 76.5Mbp). Again, these are the
two most significant genes within the region, and their positions
match those of the LRS peaks on the QTL maps (Figure 3B).
Further, we investigated the conservation of the amino acid
sequence in the proteins which our candidate genes code
for using Protein BLAST. This revealed that the proteins are
conserved between mouse and human (RXRG 99% identical;
TNR 95% identical; MCTP1 90% identical; CMYA5 68%
identical). The strong conservation of RXRG, TNR and MCTP1
supports that they may have an evolutionarily conserved
function.
Gene Expression in the Brain
The Allen Brain Atlas indicates that Rxrg and Tnr are expressed
throughout the mouse brain (Lein et al., 2007) but that Cmya5
TABLE 1 | Activity traits in the elevated zero maze which have a significant QTL.
ID Phenotype Number of lines Number of Position of
phenotyped genes genes (mm9)
12359 Central nervous system, behavior: Anxiety assay, baseline untreated control (BASE group),
activity in closed quadrants using an elevated zero maze in 60–120-day-old males and females
during first 5min [n beam breaks]
74 3 Chr1:160.6–161.5
12361 Central nervous system, behavior: Anxiety assay, baseline untreated control (BASE group),
activity in closed quadrants using an elevated zero maze in 60–120-day-old males and females
during 10min [n beam breaks]
74 8 Chr1:160.6–162.2
12409 Central nervous system, behavior: Anxiety assay, saline treated [0.18ml/kg i.p.] (NOS group),
activity in closed quadrants using an elevated zero maze in 60–120-day-old males only during
first 5min [n beam breaks]
73 30 Chr1:156.2–161.5
44 Chr1:165.3–171.0
12411 Central nervous system, behavior: Anxiety assay, saline treated [0.18ml/kg i.p.] (NOS group),
activity in closed quadrants using an elevated zero maze in 60–120-day-old males only during
10min [n beam breaks]
73 30 Chr1:156.2–161.5
7 Chr1:169.1–170.0
12419 Central nervous system, behavior: Anxiety assay, saline treated [0.18ml/kg i.p.] (NOS group),
activity in closed quadrants using an elevated zero maze in 60–120-day-old males and females
during first 5min [n beam breaks]
75 60 Chr1:156.2–164.9
9 Chr1:169.1–171.5
12420 Central nervous system, behavior: Anxiety assay, saline treated [0.18ml/kg i.p.] (NOS group),
activity in closed quadrants using an elevated zero maze in 60–120-day-old males and females
during last 5min [n beam breaks]
75 31 Chr1:156.2–162.0
12421 Central nervous system, behavior: Anxiety assay, saline treated [0.18ml/kg i.p.] (NOS group),
activity in closed quadrants using an elevated zero maze in 60–120-day-old males and females
during 10min [n beam breaks]
75 61 Chr1:157.8–165.0
9 Chr1:169.1–171.5
GeneNetwork ID, phenotype and number of lines phenotyped are from GeneNetwork, number of genes refers to the number of genes within the QTL which have human homologs.
Position identifies the chromosome and megabase pair (Mbp) location of the gene on mm9.
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FIGURE 3 | Example QTL maps showing two significant QTL within
each of the regions we identified. (A) Chromosome 1, between 155 and
175Mbp, elevated zero maze traits (GeneNetwork ID 12419, 12361 and
12409; full details in Table 1). (B) Chromosome 13, between 70 and
100Mbp, open field test traits 11606, 11759, 11607 (Full details in Table 2).
This clearly shows that some traits have two peaks, with a non-significant
region between, while other traits have significant peaks only at one end or
the other of the identified regions. The higher red line indicates the level of
genome-wide significance, i.e., a genome-wide corrected p ≤ 0.05, with the
blue line showing the significance of the trait at each position. The lower red
line indicates the negative additive coefficient, i.e., that C57BL/6J alleles
increase trait values, with the scale in green on the left. The colored blocks at
the top of the figure show the positions of genes. The orange track at the
bottom of each map is the SNP Seismograph track, showing the positions of
SNPs within the BXD lines. The location of our four candidate genes are
shown, with the width of the line representing the size of the gene.
has high expression only in the cerebellum. For Mctp1 no area
shows strong expression in the mouse brain atlas. Human RNA-
seq data from BrainSpan (Miller et al., 2014), however, suggests
an increase in expression ofMCTP1 in the striatum. TNR appears
to have a similar level of expression throughout the brain.
Interestingly, RXRG also shows high expression in the striatum
while CMYA5 shows low expression levels throughout the brain.
“Guilt-by-Association”
Next we used GeneFriends to identify genes which commonly
coexpress with our candidates, irrespective of tissue or treatment.
GeneFriends uses the gene expression omnibus database
and calculates a coexpression value and a p-value for this
coexpression. Coexpression of a gene with two of our candidates
suggests it is involved in their shared function (as a single
gene may have several functions, only some of which are
shared). We can then use WebGestalt to look for enriched
annotations in these coexpressed genes, which may indicate
how our candidate genes function to influence BD. CMYA5 had
no commonly coexpressed genes. However, MCTP1 and RXRG
have 13 commonly coexpressed genes (Supplementary Table 2),
which are significantly enriched for relevant disease annotations
(e.g., “Brain diseases” and “Mental disorders”; Supplementary
Table 3) and several relevant GO annotations (e.g., “Synaptic
transmission”; Supplementary Table 4).
RXRG and TNR share 797 commonly coexpressed genes
(Supplementary Table 5). This shows enrichment for 10 diseases,
all of which are highly relevant to neuropsychiatric disorders
(e.g., “Substance-related disorders” and “Mental disorders”;
Supplementary Table 6). GO and pathway annotations
(Supplementary Tables 7–10) show a clear relationship
to intercellular signaling (e.g., “Synaptic transmission,”
“Neuroactive ligand-receptor interaction” and “Signaling
by G protein-coupled receptors”). Interestingly, MCTP1 and
TNR share no commonly coexpressed genes. This suggests that
although genes related to, for example, mental disorders are
enriched in the overlap between TNR and RXRG, and in the
overlap between MCTP1 and RXRG, they are not the same
genes, i.e., both sets of genes are independently related to mental
disorders.
Coexpression Analysis
The GeneFriends analysis suggests that MCTP1 and RXRG
coexpress with mental disorder related genes. BrainSpan shows
that both MCTP1 and RXRG are expressed in the striatum,
and it has been found that striatal expression of Rxrg effects
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TABLE 2 | Vertical activity traits in the open field which have a significant QTL.
ID Phenotype Number of lines
phenotyped
Number of
genes
Position of
genes (mm9)
11350 Central nervous system, behavior: Novel open field behavior, vertical activity (rears) from 15 to
30min for males [n beam breaks]
63 25 Chr13:74.7–82.0
11351 Central nervous system, behavior: Novel open field behavior, vertical activity (rears) from 30 to
45min for males [n beam breaks]
63 38 Chr13:74.0–82.0
11352 Central nervous system, behavior: Novel open field behavior, vertical activity (rears) from 45 to
60min for males [n beam breaks]
63 38 Chr13:74.0–82.0
11355 Central nervous system, behavior: Novel open field behavior, vertical activity (rears) in the center
from 0 to 60min for males [n beam breaks]
63 41 Chr13:73.9–84.0
11606 Central nervous system, behavior: Novel open field behavior, vertical activity (rears) from 0 to 15
for females [n beam breaks]
64 10 Chr1:97.0–107.2
10 Chr13:93.9–94.9
11607 Central nervous system, behavior: Novel open field behavior, vertical activity (rears) from 15 to
30min for females [n beam breaks]
64 37 Chr13:75.2–95.2
11608 Central nervous system, behavior: Novel open field behavior, vertical activity (rears) from 30 to
45min for females [n beam breaks]
64 24 Chr13:75.2–83.7
11609 Central nervous system, behavior: Novel open field behavior, vertical activity (rears) from 45 to
60min for females [n beam breaks]
64 28 Chr9:73.3–78.0
26 Chr13:74.7–84.0
11612 Central nervous system, behavior: Novel open field behavior, vertical activity (rears) in the center
from 0 to 60min for females [n beam breaks]
64 38 Chr13:74.7–94.9
11759 Central nervous system, behavior: Novel open field behavior, vertical activity (rears) from 0 to
60min in the center for females [n beam breaks]
64 17 Chr13:75.8–78.7
11772 Central nervous system, behavior: Novel open field behavior, vertical activity (rears) from15 to
30min in the center for females [n beam breaks]
64 17 Chr13:75.8–78.7
11773 Central nervous system, behavior: Novel open field behavior, vertical activity (rears) from 30 to
45min in the center for females [n beam breaks]
64 15 Chr13:75.8–78.4
11784 Central nervous system, behavior: Novel open field behavior, vertical activity (rears) in the
periphery from 15 to 30min for females [n beam breaks]
64 22 Chr13:75.8–82.0
11785 Novel open field behavior, vertical activity (rears) in the periphery from 30 to 45min for females
[n beam breaks]
64 24 Chr13:75.2–83.7
11786 Central nervous system, behavior: Novel open field behavior, vertical activity (rears) in the
periphery from 45 to 60min for females [n beam breaks]
64 26 Chr13:74.7–83.6
11790 Central nervous system, behavior: Novel open field behavior, vertical activity (rears) in the
periphery from 0 to 60min for females [n beam breaks]
64 26 Chr13:74.7–83.6
11793 Central nervous system, behavior: Saline control response (10ml/kg), open field behavior, vertical
activity (rears) 0–60min after injection for females [n beam breaks/60min]
64 25 Chr13:74.7–82.0
11806 Central nervous system, behavior: Saline control response (10mg/kg ip), open field behavior,
vertical activity (rears) 0–15min after injection for females [n beam breaks/15min]
64 48 Chr13:74.7–96.3
11807 Central nervous system, behavior: Saline control response (10mg/kg ip), open field behavior,
vertical activity (rears) 15–30min after injection for females [n beam breaks/15min]
64 17 Chr13:75.2–78.7
(Continued)
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TABLE 2 | Continued
ID Phenotype Number of lines
phenotyped
Number of
genes
Position of
genes (mm9)
11808 Central nervous system, behavior: Saline control response (10mg/kg ip), open field behavior,
vertical activity (rears) 30–45min after injection for females [n beam breaks/15min]
64 17 Chr13:75.2–78.7
11809 Central nervous system, behavior: Saline control response (10mg/kg ip), open field behavior,
vertical activity (rears) 45–60min after injection for females [n beam breaks/15min]
64 17 Chr13:75.2–78.7
11863 Central nervous system, behavior: Novel open field behavior, vertical activity (rears) from 0 to
15min for males and females [n beam breaks]
64 8 Chr1:97.0–107.2
9 Chr13:93.9–94.6
11864 Central nervous system, behavior: Novel open field behavior, vertical activity (rears) from 15 to
30min for males and females [n beam breaks]
64 39 Chr13:74.4–94.6
11865 Central nervous system, behavior: Novel open field behavior, vertical activity (rears) from min
30–45 for males and females [n beam breaks]
64 34 Chr13:74.2–84.0
11866 Central nervous system, behavior: Novel open field behavior, vertical activity (rears) from 45 to
60min for males and females [n beam breaks]
64 2 Chr9:73.3–74.0
4 Chr9:77.2–78.0
40 Chr13:73.9–84.0
11869 Central nervous system, behavior: Novel open field behavior, vertical activity (rears) in the center
from 0 to 60min for males and females [n beam breaks]
64 39 Chr13:74.0–84.0
12042 Central nervous system, behavior: Novel open field behavior, vertical activity (rears) in the
periphery from 30 to 45min for males and females [n beam breaks]
64 22 Chr13:75.8–82.0
12043 Central nervous system, behavior: Novel open field behavior, vertical activity (rears) in the
periphery from 45 to 60min for males and females [n beam breaks]
64 22 Chr13:75.8–82.0
12047 Central nervous system, behavior: Novel open field behavior, vertical activity (rears) in the
periphery from 0 to 60min for males and females [n beam breaks]
64 23 Chr13:75.8–84.0
12050 Central nervous system, behavior: Saline control response (10ml/kg), open field behavior, vertical
activity (rears) 0–60min after injection for males and females [n beam breaks/60min]
64 23 Chr13:75.2–82.0
12063 Central nervous system, behavior: Saline control response (10mg/kg ip), open field behavior,
vertical activity (rears) 0–15min after injection for males and females [n beam breaks/15min]
64 23 Chr13:75.8–84.0
12064 Central nervous system, behavior: Saline control response (10mg/kg ip), open field behavior,
vertical activity (rears) 15–30min after injection for males and females [n beam breaks/15min]
64 16 Chr13:75.8–79.0
12065 Central nervous system, behavior: Saline control response (10mg/kg ip), open field behavior,
vertical activity (rears) 30–45min after injection for males and females [n beam breaks/15min]
64 16 Chr13:75.8–79.0
12066 Central nervous system, behavior: Saline control response (10mg/kg ip), open field behavior,
vertical activity (rears) 45–60min after injection for males and females [n beam breaks/15min]
64 14 Chr13:75.8–78.2
GeneNetwork ID, phenotype and number of lines phenotyped are from GeneNetwork, number of genes refers to the number of genes within the QTL which have human homologs.
Position identifies the chromosome and megabase pair (Mbp) location of the gene on mm9.
depression-like behaviors in mice (Krzyzosiak et al., 2010).
Therefore, we analyzed striatal expression of our four candidate
genes in GeneNetwork, using the HQF Striatum Exon RMA data
(GN163). This data for mouse striatal exon probes shows clear
coexpression between Mctp1, Rxrg, and Tnr (Supplementary
Table 11). We could not investigate Cmya5 exons, as no exon
probes were available. However, there are seven intronic probes
for Cmya5 which show a significant cis-eQTL and correlate
strongly with each other (r ≥ 0.5). These do not correlate with
Mctp1, Rxrg or Tnr in the striatum.
We further investigated if known mental disorder genes,
which commonly coexpress with our candidates in the
GeneFriends data, also coexpress specifically in the striatum.
Therefore, we built a Pearson correlation matrix including
our candidate genes (Cmya5, Mctp1, Rxrg, and Tnr), genes
commonly coexpressed with MCTP1 and RXRG or TNR and
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RXRGwithin themental disorders and CNSDiseases annotations
(Supplementary Tables 3, 6), and 10 genes containing SNPs which
have been strongly associated with BD (SLC6A4, BDNF, DAOA,
DTNBP1, NRG1, DISC1, CACNA1C, ANK3, ODZ4, COMT;
Szczepankiewicz, 2013; Mühleisen et al., 2014). Since there is
strong evidence for shared genetics between mental disorders it
is likely that we will see an overlap (Doherty and Owen, 2014). As
above, we only used probes specific to exons, with the exception
of Cmya5. An identical table was built for the hippocampus, as
the same mRNA microarray has been used and therefore probes
were directly comparable. Multiple comparisons were corrected
for by dividing the p-value of the correlation by the number of
probes (n = 63) targeting our four candidates (Cmya5, Mctp1,
Rxrg, Tnr). Probes were said to coexpress if they have an r ≥ 0.5
or ≤ −0.5 and an adjusted p ≤ 0.05 (p = 7.94e-4; r = 0.554 or
r = −0.554 in striatum).
The tables for striatum (Supplementary Table 11) and
hippocampus (Supplementary Table 12) show that there are
many more coexpressing probes in the striatum than in the
hippocampus. Genes with probes which consistently coexpress
with several probes for the candidate genes are shown in
Supplementary Table 13.
Interestingly, Cmya5 shows no correlation with any of these
genes, either in the hippocampus or striatum, indicating that it
may be acting in another brain region or during development.
The other three genes show strong coexpression with each other,
and with other genes related to mental disorders in the striatum,
but not in the hippocampus.
Correlation Analysis
Next, we correlated the expression of our four candidates with
the behavioral phenotypes shown in Tables 1, 2. This showed a
correlation between several Mctp1 probes (Supplementary Table
11) and the open field test phenotypes (Table 2). We can sum
up each of these groups of related traits into two principal
components, i.e., the first principal component for the Mctp1
probes and the first principal component for the open field traits
and look at the correlation between these two. The open field PC1
explains∼75% of the variance between traits and theMctp1 PC1
explains ∼60% of the variance. These two principal components
show a Pearson’s correlation of 0.562, p = 1.86e-3. This suggests
that there is a link between expression level of Mctp1 in the
striatum and vertical activity in the open field test.
We next investigated Pearson correlations between expression
of our candidates and the GeneNetwork phenotype database.
Each of the four candidates has multiple probes for striatal
expression, which were correlated against each other. We then
selected those probes that showed a significant correlation
(r ≥ 0.5) with at least one other probe (Supplementary Table
11). These selected probes were then correlated against the
GeneNetwork database of phenotypes. Supplementary Table 14
shows that the expression ofMctp1, Rxrg and Tnr correlates with
dopamine related gene expression in the striatum. Further, we
found that Cmya5 expression correlates with anxiety-like and
depression-like behavior (Supplementary Table 14). Interestingly,
when these phenotypes were correlated against our target
phenotypes (i.e., open field test and elevated zero maze traits;
Supplementary Table 15), there was no significant correlation
with dopamine related gene expression. However, this may be
due to a much lower number of overlapping samples (n = 27
rather than n = 63).
These results suggest thatMctp1, Rxrg, and Tnr may be acting
within the same striatal dopamine network, whereas Cmya5
is acting elsewhere, but still has an influence on anxiety and
depression related phenotypes.
Discussion
This study identified four candidate genes associated with anxiety
in mice and BD in humans, CMYA5, MCTP1, RXRG, and TNR.
The association between TNR and BD is a novel finding. In mice,
three of our candidates (Mctp1, Rxrg, and Tnr) coexpress in
the striatum with other genes related to mental disorders. This
suggests that these three genes are part of a pathway which is
shared between neuropsychiatric disorders, and which involves
the striatum.
Interval mapping in the BXDmouse set produces two regions,
within which the QTL for the open field traits (34 measures)
and the elevated zero maze traits (7 measures) are located (open
field at Chr1:156.2–171.5Mbp and elevated maze at Chr13:73–
97Mbp). Our results suggest that the QTL defining these two
regions are actually made up of two loci rather than one.
Firstly the QTL for some traits are found only in a small
part of each region, or have two significant loci separated by
a non-significant region (Tables 1, 2; Figure 3). Secondly, we
find one gene associated with BD at each end of these two
regions.
Distal chromosome 1 has been linked to a wide range of
phenotypes, many of them neuropsychiatric related (Flint et al.,
1995; Gershenfeld et al., 1997; Wehner et al., 1997; Turri et al.,
2001a,b; Talbot et al., 2003; Yalcin et al., 2004; Singer et al.,
2005; Valdar et al., 2006; Ponder et al., 2007; Mozhui et al.,
2008; Eisener-Dorman et al., 2010; Vogel et al., 2013). Genes
influencing related phenotypes can often collocate in the genome
(e.g., Legare et al., 2000). Often, when a trait is mapped to a single
QTL, the locus actually contains several QTL, each with a small
effect size (Flint et al., 2005; Valdar et al., 2006). Therefore, our
finding of an elevated zero maze QTL on chromosome 1 fits well
with the literature.
We find that our genes have previously been associated with
schizophrenia, which agrees with an identified overlap in the
phenotypes and genetics underlying the two disorders, as well as
other psychiatric disorders (Craddock et al., 2006; Owen et al.,
2007; Lichtenstein et al., 2009; Purcell et al., 2009; Lee et al.,
2013; Cardno and Owen, 2014; Gratten et al., 2014; Pearlson
and Ford, 2014; Ruderfer et al., 2014). All four candidates have
been associated generally with neuropsychiatric disorders, or
psychiatric-like behavior, before. Mouse Tnr knock-outs have
decreased motivation and increased anxiety (Freitag et al.,
2003), a depression-like phenotype. Further TNR appears in a
GWAS of efficacy of an antipsychotic, iloperidone, for treating
schizophrenia (Lavedan et al., 2009). There is some previous
association between RXRG and BD, as well as other disorders,
such as schizophrenia (Le-Niculescu et al., 2008, 2009). RXRG
has been associated with sensation seeking in humans (Alliey-
Rodriguez et al., 2011) and ablation of Rxrg in mice leads to
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depression-like behavior (Krzyzosiak et al., 2010). CMYA5 has
been associated with schizophrenia (Wang et al., 2014; Watanabe
et al., 2014), depression (Wang et al., 2014) and BD (Nurnberger
et al., 2014).CMYA5 interacts with dysbindin (Benson et al.,
2004), which has been linked to both schizophrenia and BD
(Breen et al., 2006; Joo et al., 2007; Pae et al., 2007). MCTP1 has
already been suggested to be associated with BD, but this result
was non-significant in their data (Scott et al., 2009).
Finally we show that three of our four genes (Mctp1, Rxrg, and
Tnr) coexpress with other genes known to be involved in mental
disorders in the striatum, but not in the hippocampus, of adult
BXD mice.
Biological Function of Candidate Genes
Our evidence identifies the striatum as a point of convergence
between three of our candidate genes,MCTP1, RXRG, and TNR.
The striatum is a relevant brain region in BD, since the diagnostic
symptoms of mania include increased risk-taking and deficits
in goal regulation (Johnson, 2005; Goodwin and Sachs, 2010),
and the striatum is involved in both of these (Balleine and
O’Doherty, 2010; Bartra et al., 2013; Mason et al., 2014). Indeed,
when making choices about risky decisions, BD patients have
increased activity in the nucleus accumbens, part of the ventral
striatum (Mason et al., 2014). This may relate back to the mouse
phenotypes, as they have to balance the rewards of exploring an
exposed area (e.g., mating opportunities) against the risks (e.g.,
predation), a system that is necessary for all animals and therefore
likely to be conserved.
RXRG
Rxrg knockout mice show a reduction in ambulatory activity
(Krezel et al., 1998), accompanied by reduction in striatal
dopamine receptor expression (Krezel et al., 1998; Krzyzosiak
et al., 2010). This alteration is due to direct transcriptional
regulation of Drd2 by retinoid receptors, such as RXRG (Samad
et al., 1997; Krezel et al., 1998; Krzyzosiak et al., 2010). In
another Rxrg knockout, expression of choline acetyltransferase
in striatal cholinergic interneurons was reduced and response
to antipsychotic dopamine antagonists was altered (Saga et al.,
1999).
These studies show that loss of RXRG signaling leads to
depression-like behavior in mice, and indicates that decreased
dopamine signaling in the striatum plays a critical role in this
(Krzyzosiak et al., 2010). Additionally, striatal dopamine receptor
expression is clearly involved in inhibition and behavioral control
(Lawrence et al., 1998; Cropley et al., 2006; Dalley et al., 2007;
Pattij et al., 2007; Hamidovic et al., 2009; Eagle et al., 2011),
a trait disrupted in the disorder. This supports that mutations
in RXRG potentially play a role in BD. Since both Mctp1 and
Tnr expression correlated with dopamine traits and with Rxrg,
it follows that they may be part of this same network.
MCTP1
MCTP1 is an understudied gene, however one of the studies has
demonstrated that MCTP1 is a calcium binding protein (Shin
et al., 2005). It has been suggested that MCTP1’s calcium binding
properties may be involved in BD (Scott et al., 2009) as other
calcium-related genes are associated with BD, such as CACNA1C
(Ferreira et al., 2008). We find that the calcium signaling pathway
is enriched in genes commonly coexpressed with RXRG and TNR
(Supplementary Table 8), and disruptions in calcium signaling
are part of the pathophysiology of bipolar disorder (Berridge,
2013, 2014). In relation to the above, MCTP1 could be part
of an intracellular signaling pathway activated by RXRG or
dopamine, or part of a calcium dependent system of regulating
dopamine receptor expression, however this hypothesis remains
to be tested.
TNR
Tnr knockout mice show decreased motivation to explore and
increased anxiety (Freitag et al., 2003). Further, knockout mice
spent more time resting and less time eating/drinking (Freitag
et al., 2003) and again, activity and appetite are altered in
BD (Goodwin and Jamison, 1990). In contrast to this, another
Tnr knockout experiment showed no increase in anxiety, but
increased exploration, although with a different pattern than the
wildtype, and an impaired ability to construct a goal-independent
representation of space (Montag-Sallaz and Montag, 2003),
whichmay be linked to disruption of goal-orientated behaviors in
bipolar patients. These differences may be due to different genetic
backgrounds. Freitag et al. backcrossed their mice to C57Bl/6J
twice, while Montag-Sallaz and Montag backcrossed to C57Bl/6J
10 times, and therefore may be indicative of epistatic interactions
TNR is a major component of the perineuronal nets (PNNs)
of inhibitory interneurons, including those in the striatum
(Fuss et al., 1993; Hargus et al., 2008). PNNs are part of the
extracellular matrix and ensheath many CNS neurons and their
axons and dendritic processes, but not the sites of synaptic
contact (Ojima et al., 1995; Alpár et al., 2006; Brückner et al.,
2006; Bitanihirwe and Woo, 2014). Specific removal of striatal
PNNs in adult mice has direct behavioral consequences (Lee
et al., 2012). Further, dysfunction of PNNs has been implicated
in schizophrenia (Bitanihirwe and Woo, 2014). In Tnr knockout
mice the composition and formation of PNNs is significantly
altered (Brückner et al., 2000; Haunsø et al., 2000). Therefore,
dysregulation of TNR may affect the PNNs of striatal cells and
consequently connectivity between cells.
Role of Striatum
Medium spiny neurons are the principal neurons of the
striatum. Supplementary Table 14 shows that Mctp1, Rxrg,
and Tnr expression correlates with gene expression signatures
for medium spiny neurons. These GABAergic neurons are
regulated by glutamatergic and dopaminergic neurons,
and presynaptic receptors (including kappa opioid and
muscarinic receptors) regulate glutamatergic and dopaminergic
transmission (McGinty, 1999). The postsynaptic glutamatergic,
dopamine D1 and D2, and muscarinic receptor signals in the
medium spiny neurons trigger a complex intracellular network,
resulting in changes in gene and protein expression (McGinty,
1999; Surmeier et al., 2007). In our list of genes which coexpress
withMctp1, Rxrg, and Tnr in the striatum (Supplementary Table
13) we find four GABA receptors, five glutamate receptors and
the kappa 1 opioid receptor, further demonstrating a potential
link to the above network. Although the full details of the
molecular mechanisms remain to be established, especially as
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different subtypes of striatal neurons express different genes
(Surmeier et al., 2007), it is interesting to note that many of these
intracellular cascades are Ca2+-dependent (McGinty, 1999). The
latter may link back to MCTP1 and the role of calcium in bipolar
disorder (Berridge, 2013, 2014). Further, medium spiny neurons
are a major downstream target of parvalbumin-positive cells,
which PNNs particularly colocalize with (Lee et al., 2012).
Conclusion
The large number of commonly coexpressed genes between
RXRG and TNR, and the enrichment of these genes in mental
disorder related annotations, strongly suggests that they are
part of the same mental disorder related network. Synaptic
transmission related genes are enriched in the commonly
coexpressed genes shared between RXRG and MCTP1 and
between RXRG and TNR. Therefore, we hypothesize that
disruption of MCTP1, RXRG or TNR alters the complex
intercellular signaling within the striatum, leading to changes in
intracellular signaling and gene expression. Overall, our study
provides evidence for the association of CMYA5,MCTP1, RXRG,
and TNR with bipolar disorder.
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Supplementary Figure 1 | Whole genome QTL maps for all elevated zero
maze phenotypes (full details in Table 1). Chromosome numbers are shown at
the top of each map and megabase pair positions within each chromosome are
shown below each map. The higher red line indicates the level of genome-wide
significance, i.e., a genome-wide corrected p ≤ 0.05, with the blue line showing
the significance of the trait at each position. Significance thresholds are shown in
the upper left corner, the significant LRS being equivalent to a genome-wide
corrected p ≤ 0.05. The upper right corner shows the trait ID, as shown in
Table 1. The lower red or green line shows the additive coefficient, where a
positive additive coefficient (green line) indicates that DBA/2J alleles increase trait
values while a negative additive coefficient (red line) indicates that C57BL/6J
alleles increase trait values. The scale for the additive coefficient is shown in green
on the left of each map.
Supplementary Figure 2 | Whole genome QTL maps for all open field test
phenotypes (full details in Table 2). Chromosome numbers are shown at the
top of each map and megabase pair positions within each chromosome are
shown below each map. The higher red line indicates the level of genome-wide
significance, i.e., a genome-wide corrected p ≤ 0.05, with the blue line showing
the significance of the trait at each position. Significance thresholds are shown in
the upper left corner, the significant LRS being equivalent to a genome-wide
corrected p ≤ 0.05. The upper right corner shows the trait ID, as shown in
Table 2. The lower red or green line shows the additive coefficient, where a
positive additive coefficient (green line) indicates that DBA/2J alleles increase trait
values while a negative additive coefficient (red line) indicates that C57BL/6J
alleles increase trait values. The scale for the additive coefficient is shown in green
on the left of each map.
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